GPT and metabolic dysfunction-associated steatohepatitis: Potential to be approved Relative decrease in liver fat Significant improvement in steatohepatitis Significant reductions in ALT and AST levels, atherogenic lipids, lipo-protein(a), markers of inflammation and fibrosis as well as improvement in NASH on liver biopsies